ACS Nano,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 11, 2025
In
this
work,
a
multifunctional
Pd@Au
nanoframe
hydrogel
was
designed
to
detect
uric
acid
(UA)
for
in
situ
monitoring
of
wound
infection
and
enhance
healing
by
chemo-photothermal
strategy.
acidic
conditions,
the
hydrogels
show
high
peroxidase-like
activity
catalyzing
H2O2
produce
reactive
oxygen
species
(ROS)
damage
RNAs
bacteria
antibacterial
activity.
Under
Near-infrared
(NIR)
laser
irradiation,
exhibit
photothermal
conversion
performance;
i.e.,
color
solution
varies
from
deep
blue
(0
s,
25.4
°C)
red
(300
50.1
infrared
thermography.
After
loading
mupirocin
(M),
as-obtained
M
maximum
cumulative
release
rate
exceeding
90%
mupirocin,
as
controlled
NIR
irradiation.
antimicrobial
experiments
vitro,
laser-driven
ability;
98%
Escherichia
coli
are
effectively
killed
10
min.
coating
rabbit
wounds
with
UA
sensing
patch
hydrogels,
status
can
be
monitored
real
time
detecting
concentration,
leading
rapid
4
days
new
synergistic
effect
This
approach
successfully
confirms
closed-loop
strategy,
real-time
efficiently
perform
therapy,
combining
functional
pharmaceutical
antibacterials.
Journal of the American Chemical Society,
Journal Year:
2024,
Volume and Issue:
146(9), P. 6252 - 6265
Published: Feb. 20, 2024
Conventional
photodynamic
therapy
(PDT)
is
often
limited
in
treating
solid
tumors
due
to
hypoxic
conditions
that
impede
the
generation
of
reactive
oxygen
species
(ROS),
which
are
critical
for
therapeutic
efficacy.
To
address
this
issue,
a
fractionated
PDT
protocol
has
been
suggested,
wherein
light
irradiation
administered
stages
separated
by
dark
intervals
permit
recovery
during
these
breaks.
However,
current
photosensitizers
used
incapable
sustaining
ROS
production
intervals,
leading
suboptimal
outcomes
(Table
S1).
circumvent
drawback,
we
have
synthesized
novel
photosensitizer
based
on
triple-anthracene
derivative
designed
prolonged
generation,
even
after
cessation
exposure.
Our
study
reveals
unique
action
derivatives,
facilitating
direct
and
effective
disruption
biomolecules
significantly
improving
efficacy
S2).
Moreover,
existing
lack
imaging
capabilities
monitoring,
constraints
fine-tuning
parameters
also
serves
as
an
afterglow
agent,
emitting
sustained
luminescence
postirradiation.
This
function
allows
precise
optimization
between
sessions
aids
determining
timing
subsequent
irradiation,
thus
enabling
meticulous
control
over
parameters.
Utilizing
our
photosensitizer,
formulated
regimen
effectively
eliminates
orthotopic
pancreatic
tumors.
investigation
highlights
promise
employing
long-persistent
activity
advanced
approaches
overcome
limitations
tumor
treatment.
Molecular Cancer,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: May 21, 2024
Abstract
Proteolysis-targeting
chimeras
(PROTACs)
technology
has
garnered
significant
attention
over
the
last
10
years,
representing
a
burgeoning
therapeutic
approach
with
potential
to
address
pathogenic
proteins
that
have
historically
posed
challenges
for
traditional
small-molecule
inhibitors.
PROTACs
exploit
endogenous
E3
ubiquitin
ligases
facilitate
degradation
of
interest
(POIs)
through
ubiquitin–proteasome
system
(UPS)
in
cyclic
catalytic
manner.
Despite
recent
endeavors
advance
utilization
clinical
settings,
majority
fail
progress
beyond
preclinical
phase
drug
development.
There
are
multiple
factors
impeding
market
entry
PROTACs,
insufficiently
precise
favorable
POIs
standing
out
as
one
most
formidable
obstacles.
Recently,
there
been
exploration
new-generation
advanced
including
PROTAC
prodrugs,
biomacromolecule-PROTAC
conjugates,
and
nano-PROTACs,
improve
vivo
efficacy
PROTACs.
These
improved
possess
capability
mitigate
undesirable
physicochemical
characteristics
inherent
thereby
enhancing
their
targetability
reducing
off-target
side
effects.
The
will
mark
pivotal
turning
point
realm
targeted
protein
degradation.
In
this
comprehensive
review,
we
meticulously
summarized
state-of-the-art
advancements
achieved
by
these
cutting-edge
elucidated
underlying
design
principles,
deliberated
upon
prevailing
encountered,
provided
an
insightful
outlook
on
future
prospects
within
field.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: Nov. 6, 2024
Abstract
Targeted
protein
degradation
(TPD)
represents
a
revolutionary
therapeutic
strategy
in
disease
management,
providing
stark
contrast
to
traditional
approaches
like
small
molecule
inhibitors
that
primarily
focus
on
inhibiting
function.
This
advanced
technology
capitalizes
the
cell’s
intrinsic
proteolytic
systems,
including
proteasome
and
lysosomal
pathways,
selectively
eliminate
disease-causing
proteins.
TPD
not
only
enhances
efficacy
of
treatments
but
also
expands
scope
applications.
Despite
its
considerable
potential,
faces
challenges
related
properties
drugs
their
rational
design.
review
thoroughly
explores
mechanisms
clinical
advancements
TPD,
from
initial
conceptualization
practical
implementation,
with
particular
proteolysis-targeting
chimeras
molecular
glues.
In
addition,
delves
into
emerging
technologies
methodologies
aimed
at
addressing
these
enhancing
efficacy.
We
discuss
significant
trials
highlight
promising
outcomes
associated
drugs,
illustrating
potential
transform
treatment
landscape.
Furthermore,
considers
benefits
combining
other
therapies
enhance
overall
effectiveness
overcome
drug
resistance.
The
future
directions
applications
are
explored,
presenting
an
optimistic
perspective
further
innovations.
By
offering
comprehensive
overview
current
innovations
faced,
this
assesses
transformative
revolutionizing
development
setting
stage
for
new
era
medical
therapy.
Nanoscale,
Journal Year:
2024,
Volume and Issue:
16(9), P. 4378 - 4391
Published: Jan. 1, 2024
Schematic
illustration
of
the
combinational
strategy
nanotechnology
and
PROTACs
(Nano-PROTACs):
typical
shortcomings
traditional
nanotechnology-based
strategies
for
PROTAC
drugs
optimization.
Chemical Science,
Journal Year:
2024,
Volume and Issue:
15(31), P. 12234 - 12257
Published: Jan. 1, 2024
Photodynamic
therapy
(PDT)
has
been
developed
as
a
potential
cancer
treatment
approach
owing
to
its
non-invasiveness,
spatiotemporal
control
and
limited
side
effects.
Currently,
great
efforts
have
made
improve
the
PDT
effect
in
terms
of
safety
efficiency.
In
this
review,
we
highlight
recent
advances
innovative
strategies
for
enhanced
PDT,
including
(1)
development
novel
radicals,
(2)
design
activatable
photosensitizers
based
on
TME
light,
(3)
photocatalytic
NADH
oxidation
damage
mitochondrial
electron
transport
chain.
Additionally,
new
mechanisms
are
also
presented
an
inspiration
PSs.
Finally,
discuss
current
challenges
future
prospects
clinical
practice
these
strategies.
It
is
hoped
that
review
will
provide
angle
understanding
relationship
between
intratumoural
redox
environment
mechanisms,
ideas
smart
systems.
Journal of the American Chemical Society,
Journal Year:
2024,
Volume and Issue:
146(15), P. 10753 - 10766
Published: April 5, 2024
Proteolysis
targeting
chimera
(PROTAC)
technology
is
an
innovative
strategy
for
cancer
therapy,
which,
however,
suffers
from
poor
delivery
and
limited
capability
protein
of
interest
(POI)
degradation.
Here,
we
report
a
the
in
situ
formulation
antineoplastic
Supra-PROTACs
via
intracellular
sulfatase-responsive
assembly
peptides.
Coassembling
sulfated
peptide
with
two
ligands
binding
to
ubiquitin
VHL
Bcl-xL
leads
formation
pro-Supra-PROTAC,
which
ratio
rationally
optimized
based
on
their
affinity.
The
resulting
pro-Supra-PROTAC
precisely
undergoes
enzyme-responsive
into
nanofibrous
cells
overexpressing
sulfatase.
Mechanistic
studies
reveal
that
pro-Supra-PROTACs
selectively
cause
apparent
cytotoxicity
through
degradation
activation
caspase-dependent
apoptosis,
during
ligand
improves
bioactivity
POI
cell
death.
In
vivo
show
enhanced
tumor
accumulation
retention
pro-Supra-PROTACs,
as
well
inhibiting
growth
excellent
biosafety
when
coadministrating
chemodrugs.
Our
findings
provide
new
approach
enzyme-regulated
peptides
living
development
PROTACs
high
delivering
efficiency.
Biochemistry,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 10, 2025
Proteolysis-targeting
chimeras
(PROTACs)
represent
a
transformative
advancement
in
drug
discovery,
offering
method
to
degrade
specific
intracellular
proteins.
Unlike
traditional
inhibitors,
PROTACs
are
bifunctional
molecules
that
target
proteins
for
elimination,
enabling
the
potential
treatment
of
previously
"undruggable"
This
concept,
pioneered
by
Crews
and
his
team,
introduced
use
small
link
protein
an
E3
ubiquitin
ligase,
inducing
ubiquitination
subsequent
degradation
protein.
By
promoting
rather
than
merely
inhibiting
function,
present
novel
therapeutic
strategy
with
enhanced
specificity
effectiveness,
especially
areas
such
as
cancer
neurodegenerative
diseases.
Since
their
initial
field
PROTAC
research
has
rapidly
expanded
numerous
now
designed
wide
range
disease-relevant
The
substantial
research,
investment,
collaboration
across
academia
pharmaceutical
industry
reflect
growing
interest
PROTACs.
Review
discusses
journey
from
discovery
clinical
trials,
highlighting
advancements
challenges.
Additionally,
recent
developments
fluorescent
photogenic
PROTACs,
used
real-time
tracking
degradation,
presented,
showcasing
evolving
targeted
therapy.
